Home About Us Company Profile

ABOUT US

About Botanicure

Founded in 2002, Botanicure Co., Ltd. is a Taiwan-based biopharmaceutical company dedicated to the development of innovative botanical medicines. With its R&D center in the Tainan Science Park and headquarters in Taipei, Botanicure develops innovative botanical therapeutics for diseases with high unmet medical needs, including dementia, chronic wound care, and regenerative medicine.

By integrating GACP-compliant cultivation standards, proprietary MTST technology, and extensive regulatory expertise, Botanicure has established a comprehensive botanical medicines development platform. As one of the first companies worldwide to successfully complete a U.S. FDA Phase IIa clinical trial for a botanical medicines targeting dementia, Botanicure continues to advance innovative therapies for neurological and aging-related diseases.

We believe botanical medicines are not merely a niche therapeutic category, but an important frontier in the future of global healthcare.

Integrity First, Innovation Forward.
Creating New Value in Healthcare Together.

Integrity

Building trust through professionalism, quality, and accountability.

Altruism

Advancing healthcare to improve lives and benefit society.

Innovation

Advancing science to unlock new possibilities in medicine.

Sharing

Partnering globally to create a healthier and more sustainable future.

Botanicure Patent Portfolio

Botanicure holds 2 patent families and over 20 patent certificates, with granted invention patents in more than 20 countries across Europe, North America, and other major markets. These patents reflect the company's strong R&D capabilities and innovation in therapeutic development.

ALL_marqueepic_certificate_25I23_YYpW4Ej2eU

R&D Excellence

Botanicure operates a pharmaceutical pilot plant, a QMS-certified Medical Device facility, and a professional cosmetics manufacturing plant. Its facilities are certified to ISO 13485, ISO 22716, ISO 9001, and ISO/IEC 17025, with the cosmetics facility also holding Indonesian Halal (LPPOM MUI) certification. Backed by years of experience in pharmaceutical and medical device innovation, Botanicure has established internationally aligned quality management systems and proprietary technology platforms. From Design & Development, CDMO/CMO, and Regulatory Affairs to commercialization strategy, Botanicure delivers end-to-end capabilities that accelerate innovation from concept to market.

Our Journey / Milestones

2026.06

Showcased Botanicure at BIO International Convention 2026, expanding international partnerships.

2025.10

First patient enrolled in the 300-subject BOTA-NS1 clinical study.

2025.09

Officially certified by the Taiwan government as a cosmetics manufacturing facility compliant with ISO 22716 standards.

2025.07

Celludoxa Sanovazo Wound Dressing (Class II Medical Device from TFDA) obtained a new indication for the prevention and management of symptoms or minor wounds caused by radiation therapy.

2025

Entered a new era of growth and transformation for Botanicure Biomedicine.

2024

Established a dedicated expert team for botanical medicines development.

2020

TFDA approved as a Class II Medical Device in Taiwan.

2019

Conducted pharmacological studies for pulmonary fibrosis.

2017-2018

Conducted pharmacological studies for dry eye disease.

2016

Conducted U.S. FDA Phase IIa clinical trials for BAC.

2015

Conducted pharmacological studies for dementia.

2014

Conducted U.S. FDA to initiate Phase II clinical trials for CSTC1 for the treatment of diabetic foot ulcers.

2006-2013

Conducted pharmacological studies for dermatitis and arthritis.

2003-2005

Completed safety and cellular pharmacology studies; launched topical healthcare products.

2002

Established R&D and manufacturing operations in the Tainan Science Park, Taiwan.

Awards & Recognitions

2023

Golden Ship Award Recognition

Botanicure received the 5th Golden Ship Award and was honored with a presidential reception. The company was recognized for its outstanding achievements in botanical medicines development, innovation, market expansion, and customer service, contributing significantly to the growth of Taiwan’s biotechnology industry.

2022

National Pharmaceutical Technology & Research Development Award (Bronze Award)

Botanicure was awarded the Bronze Award in the Pharmaceutical Category at the National Pharmaceutical Technology & Research Development Award, jointly organized by Taiwan’s Ministry of Health and Welfare and Ministry of Economic Affairs. The award recognizes excellence in pharmaceutical innovation and R&D achievements.

2021

Multiple Innovation Awards for Celludoxa Sanovazo

- National Innovation Award – Enterprise Innovation Award
- Asia-Pacific Beauty Industry Excellence Award – Industry Benchmark Award
- International Innovation Award from the Asian Enterprise Chamber
- Finalist of the Drug Technology Research & Development Award by the Ministry of Health and Welfare

2011

Government Grant for Diabetic Wound Healing Product Development

Botanicure’s CSTC patented extract for diabetic wound healing product development received funding under the Biotechnology R&D Commercialization Promotion Program of Taiwan’s Ministry of Economic Affairs.

2004

National Biotechnology & Medical Quality Recognition

National Biotechnology & Medical Quality Recognition
Botanicure was recognized as a finalist in the National Biotechnology and Medical Quality Award organized by the Taiwan Bio Industry Organization and received the Diamond Award for Premium Products.